Viewing StudyNCT02617589



Ignite Creation Date: 2024-05-06 @ 7:51 AM
Last Modification Date: 2024-10-26 @ 11:53 AM
Study NCT ID: NCT02617589
Status: COMPLETED
Last Update Posted: 2023-03-28
First Post: 2015-11-26

Brief Title: An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide Each Given With Radiation Therapy for Newly-diagnosed Patients With Glioblastoma GBM a Malignant Brain Cancer
Sponsor:
Organization: Bristol-Myers Squibb

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count: 560
Enrollment Type: ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Name
PHASE3
Observational Models:
Time Perspective List:
Who Masked List: